XML 39 R27.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Segment Information and Concentration of Business Risk (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Segment Information and Concentration of Business Risk [Abstract] |
Segment Information | The following tables show our segment revenue and income (loss) from operations for 2019, 2018 and 2017 (in thousands), respectively.
2019 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 292,992 |  |  | $ | — |  |  | $ | — |  |  | $ | 292,992 |
Product sales, net |  |  | — |  |  |  | 42,253 |  |  |  | — |  |  |  | 42,253 |
Licensing and other royalty revenue |  |  | 12,616 |  |  |  | 10,172 |  |  |  | (5,583 | ) |  |  | 17,205 |
Total commercial revenue |  |  | 305,608 |  |  |  | 52,425 |  |  |  | (5,583 | ) |  |  | 352,450 |
R&D revenue under collaborative agreements |  |  | 553,038 |  |  |  | 436,118 |  |  |  | (219,007 | ) |  |  | 770,149 |
Total segment revenue |  | $ | 858,646 |  |  | $ | 488,543 |  |  | $ | (224,590 | ) |  | $ | 1,122,599 |
Total operating expenses |  | $ | 523,207 |  |  | $ | 450,469 |  |  | $ | (216,960 | ) |  | $ | 756,716 |
Income (loss) from operations |  | $ | 335,439 |  |  | $ | 38,074 |  |  | $ | (7,630 | ) |  | $ | 365,883 |
2018 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 237,930 |  |  | $ | — |  |  | $ | — |  |  | $ | 237,930 |
TEGSEDI product sales, net |  |  | — |  |  |  | 2,237 |  |  |  | — |  |  |  | 2,237 |
Licensing and other royalty revenue |  |  | 2,755 |  |  |  | 12,000 |  |  |  | — |  |  |  | 14,755 |
Total commercial revenue |  |  | 240,685 |  |  |  | 14,237 |  |  |  | — |  |  |  | 254,922 |
R&D revenue under collaborative agreements |  |  | 401,259 |  |  |  | 50,630 |  |  |  | (107,137 | ) |  |  | 344,752 |
Total segment revenue |  | $ | 641,944 |  |  | $ | 64,867 |  |  | $ | (107,137 | ) |  | $ | 599,674 |
Total operating expenses |  | $ | 380,212 |  |  | $ | 295,683 |  |  | $ | (14,849 | ) |  | $ | 661,046 |
Income (loss) from operations |  | $ | 261,732 |  |  | $ | (230,816 | ) |  | $ | (92,288 | ) |  | $ | (61,372 | )
2017 |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
Revenue: |  |  |  |  |  |  |  |  |  |  |  |
Commercial revenue: |  |  |  |  |  |  |  |  |  |  |  |
SPINRAZA royalties |  | $ | 112,540 |  |  | $ | — |  |  | $ | — |  |  | $ | 112,540 |
Licensing and other royalty revenue |  |  | 7,474 |  |  |  | — |  |  |  | — |  |  |  | 7,474 |
Total commercial revenue |  |  | 120,014 |  |  |  | — |  |  |  | — |  |  |  | 120,014 |
R&D revenue under collaborative agreements |  |  | 405,171 |  |  |  | 43,401 |  |  |  | (54,407 | ) |  |  | 394,165 |
Total segment revenue |  | $ | 525,185 |  |  | $ | 43,401 |  |  | $ | (54,407 | ) |  | $ | 514,179 |
Total operating expenses |  | $ | 373,788 |  |  | $ | 163,871 |  |  | $ | (54,527 | ) |  | $ | 483,132 |
Income (loss) from operations |  | $ | 151,397 |  |  | $ | (120,470 | ) |  | $ | 120 |  |  | $ | 31,047 |
The following table shows our total assets by segment at December 31, 2019 and 2018 (in thousands), respectively.
Total Assets |  | Ionis Core |  |  | Akcea Therapeutics |  |  | Elimination of Intercompany Activity |  |  | Total |
December 31, 2019 |  | $ | 3,478,081 |  |  | $ | 599,250 |  |  | $ | (844,219 | ) |  | $ | 3,233,112 |
December 31, 2018 |  | $ | 2,975,491 |  |  | $ | 365,261 |  |  | $ | (672,968 | ) |  | $ | 2,667,784 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration